. 2022 Aug 23;29(6):883–887. doi: 10.1093/ibd/izac174
© The Author(s) 2022. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
Figure 1.
Severity of symptoms by system for dose 3 relative to dose 2.